Home » Newsletters » BioWorld Science

BioWorld Science

March 7, 2018

View Archived Issues

CARB-X commits financing to support MicuRx's development of polymyxin antibiotic MRX-8

FDA approves Moleac's IND application for MLC-1501 post-stroke recovery program

FDA allows IND application for ND-L02-s0201 for idiopathic pulmonary fibrosis to proceed

miR-511-3p shown to modulate allergic inflammation through CCL2

FDA accepts NDA for prucalopride for chronic idiopathic constipation

EMA accepts regulatory submission for Forxiga in adults with type 1 diabetes

New Eli Lilly GPR40 agonist LY-3104607 shows glucose-lowering potential

Takeda applies for approval of relugolix for uterine fibrosis in Japan

Bristol-Myers Squibb sBLA update approved by FDA for Opdivo

PMN-310 shows similar blood-brain barrier penetration as aducanumab

European Commission approves Ameluz with daylight PDT

FDA grants orphan drug designation to PTG-300 for beta-thalassemia

Celgene completes Juno Therapeutics acquisition

FDA approves Latuda for treatment of bipolar depression in pediatric patients

Bavarian Nordic describes phase II results for universal respiratory syncytial virus vaccine

First patient enrolled in TOPAZ trial of suprachoroidal CLS-TA in retinal vein occlusion

Themis and CEPI partner on vaccines for Lassa fever and MERS

Targeting P2Y6 receptor modulates allergic lung inflammation

FDA grants allowance of IND for FCX-013 gene therapy for scleroderma

Enrollment completed in phase III study of S-588410 for esophageal cancer

FDA approves Trogarzo for multidrug-resistant HIV-1

Ligand grants Roivant rights to glucagon receptor antagonist LGD-6972

Apexigen and the Pediatric Brain Tumor Consortium collaborate on trial of APX-005M

Hetero Labs discovers novel betulinic acid analogues

Splunc1-knockout mice found more susceptible to HDM-induced inflammation

Novel MAP4K2/ACK-1 kinase inhibitors identified at KIST

Rigel Pharmaceuticals patents novel AMPK activators

Vidac Pharma identifies new anticancer piperazine derivatives

Allena initiates phase III trial of ALLN-177 in patients with enteric hyperoxaluria

Anti-heroin vaccine demonstrates efficacy in rodents

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...